Cart
sales@molnova.com
ORM-10921
CAS No. 610782-82-6
ORM-10921( —— )
Catalog No. M34365 CAS No. 610782-82-6
ORM-10921 is an α2C-adrenoceptor antagonist that has shown antipsychotic and antidepressant activity in animal studies.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 603 | Get Quote |
|
| 5MG | 922 | Get Quote |
|
| 10MG | 1226 | Get Quote |
|
| 25MG | 1794 | Get Quote |
|
| 50MG | 2410 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameORM-10921
-
NoteResearch use only, not for human use.
-
Brief DescriptionORM-10921 is an α2C-adrenoceptor antagonist that has shown antipsychotic and antidepressant activity in animal studies.
-
DescriptionORM-10921 free base is a selective α-2C adrenergic receptor antagonist with a Ki of 1.4 nM. ORM-10921 free base displays potent antidepressant and antipsychotic-like effects.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetAdrenergic Receptor
-
RecptorAdrenergic Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number610782-82-6
-
Formula Weight285.38
-
Molecular FormulaC18H23NO2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(OC)[C@]1(C)[C@]2(C3=C(C=4C(O3)=CC=CC4)CCN2CCC1)[H]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Jukka Sallinen, et al. Pharmacological characterisation of a structurally novel α2C-adrenoceptor antagonist ORM-10921 and its effects in neuropsychiatric models. Basic Clin Pharmacol Toxicol. 2013 Oct;113(4):239-49.?
molnova catalog
related products
-
LY377604
LY377604 is a human β3-adrenergic receptor agonist (EC50: 2.4 nM) and β1/2-adrenergic receptor antagonist for the study of obesity.
-
Guanabenz acetate
An α2 adrenergic receptor that is used as an antihypertensive drug.
-
(S)-(-)-Propranolol ...
(S)-(-)-Propranolol hydrochloride, an adrenergic receptor antagonist, exhibits potential anticancer activity and may enhance the prognosis of burn patients.
